Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      Botox Banner v2 D 3
      Botox Banner v2 M 2

      UK-BUO-250026. DOP: May 2025.

      Treatment options for overactive bladder (OAB)

      The treatment of OAB is aimed at reducing symptoms to improve patients’ overall quality of life.

      Treatments for OAB include:6

      • Lifestyle interventions
      • Containment
      • Pharmacotherapy
      • Botulinum toxin type A
      • Posterior tibial nerve stimulation
      • Sacral nerve stimulation
      • Surgery

      Lifestyle interventions for OAB include weight reduction, reduced caffeine intake, bladder training, modified fluid intake and pelvic floor muscle training.6

      Lifestyle interventions for OAB include weight reduction, reduced caffeine intake, bladder training, modified fluid intake and pelvic floor muscle training.6

      Lifestyle interventions for OAB include weight reduction, reduced caffeine intake, bladder training, modified fluid intake and pelvic floor muscle training.6

      Lifestyle interventions for OAB include weight reduction, reduced caffeine intake, bladder training, modified fluid intake and pelvic floor muscle training.6

      Lifestyle interventions for OAB include weight reduction, reduced caffeine intake, bladder training, modified fluid intake and pelvic floor muscle training.6

      OAB is a complex, multi-symptom syndrome that can be difficult to treat13

      OAB: overactive bladder.

      BOTOX® for OAB

       

      ©NICE [2019] Urinary incontinence and pelvic organ prolapse in women: management. Available from nice.org.uk. All rights reserved. Subject to Notice of rights

      NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. National Institute for Health and Care Excellence (NICE). NG123: Urinary incontinence and pelvic organ prolapse in women: management. Available at: https://www.nice.org.uk/guidance/ng123. Accessed June 2025.
      7. Chapple C R, Yamanishi T and Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60(5):82-88
      8. Castro D, Miranda P et al. Assessment of reasons for overactive bladder treatment change. Acta Urol Esp. 2011;35:73–9
      9. Benner J S, Nichol M et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105:1276–82
      10. European Association of Urology (EAU) Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms. Available at: https://uroweb.org/guidelines/non-neurogenic-female-luts. Accessed June 2025.
      11. Oerlemans DJAJ, van Kerrebrock PEV. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neururol Urodyn. 2008;27:28–33
      12. Sanford M T and Suskind A M. Neuromodulation in neurogenic bladder. Transl Abdrol Urol. 2016;5:117-126
      13. Starkman J S, Smith C P and Staskin D R. Surgical options for drug-refractory overactive bladder patients. Reviews in Urology. 2010;12(2-3):e97

       

      ©NICE [2019] Urinary incontinence and pelvic organ prolapse in women: management. Available from nice.org.uk. All rights reserved. Subject to Notice of rights

      NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. National Institute for Health and Care Excellence (NICE). NG123: Urinary incontinence and pelvic organ prolapse in women: management. Available at: https://www.nice.org.uk/guidance/ng123. Accessed June 2025.
      7. Chapple C R, Yamanishi T and Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 2002;60(5):82-88
      8. Castro D, Miranda P et al. Assessment of reasons for overactive bladder treatment change. Acta Urol Esp. 2011;35:73–9
      9. Benner J S, Nichol M et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105:1276–82
      10. EAU Guidelines on Urinary Incontinence in Adults. Available at: https://d56bochluxqnz.cloudfront.net/media/EAU-Guidelines-on-Urinary-Incontinence-2020.pdf. Accessed June 2025.
      11. Oerlemans DJAJ, van Kerrebrock PEV. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neururol Urodyn. 2008;27:28–33
      12. Sanford M T and Suskind A M. Neuromodulation in neurogenic bladder. Transl Abdrol Urol. 2016;5:117-126
      13. Starkman J S, Smith C P and Staskin D R. Surgical options for drug-refractory overactive bladder patients. Reviews in Urology. 2010;12(2-3):e97

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: June 2025. UK-BUO-250054.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250400. Date of preparation December 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.